Letter: mesalazine—a safe drug with rare serious adverse events
Open Access
- 19 May 2020
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (11), 1210-1211
- https://doi.org/10.1111/apt.15691
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Mesalamine-Associated Sinus BradycardiaClinical Journal of Sport Medicine, 2019
- Systematic review: safety of mesalazine in ulcerative colitisAlimentary Pharmacology & Therapeutics, 2018
- Systematic review with meta‐analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2018
- Mesalamine Associated BradycardiaCureus, 2018
- Systematic review with network meta‐analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2015
- Bradicardia sinusal asociada a la administración oral de mesalazinaMedicina Clinica, 2006
- SEVERE SYMPTOMATIC SINUS BRADYCARDIA ASSOCIATED WITH MESALAMINE USEThe American Journal of Gastroenterology, 1998